A clinical approach to dementia with Lewy bodies

Neurologist

Volumn 5, Issue 5, 1999, Pages 247-257

  Galasko, D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Dementia; Lewy body; Parkinson's disease

Indexed keywords

CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRAZODONE; VALPROIC ACID;

AGING; ALERTNESS; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BLOOD TOXICITY; BRAIN REGION; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DEMENTIA; DEPRESSION; HUMAN; LEWY BODY; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; VISUAL HALLUCINATION;

EID: 0032825604     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-199909000-00002     Document Type: Review

References (82)

1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies. (DLB): Report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-24.
2. Ellis RJ, Caligiuri M, Galasko D, Thai LJ: Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alz Dis Assoc Disord 1996;10:103-14.
3. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990;237: 197-204.
4. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95:119-39.
5. Bergeron C, Pollanen M. Lewy bodies in Alzheimer disease: One or two diseases? Alz Dis Assoc Disord 1989;3:197-204.
6. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 1990;95: 239-58.
7. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-95.
8. Gibb WRG, Esiri, MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110:1131-53.
9. Dickson DW, Ruan D, Crystal H, Mark MH, Davies P, Kress Y, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2-3 neuntes specific to DLBD. Neurology 1991;41:1402-9.
10. Hansen L, Salmon DP, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: A clinical and pathological entity. Neurology 1990;40:1-8.
11. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754-60.
12. Lennox G, Lowe J, Landon M, Byrne EJ, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease: Correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989;52:1236-47.
13. Hughes D, Daniel S, Blankson, S, Lees A. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8.
14. de Vos RAI, Jansen ENH, Stam FC, Ravid R, Swaab DF. "Lewy body disease": Clinico-pathological correlation in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 1995;97:13-22.
15. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570-6.
16. Mattilla PM, Roytta, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol 1998;95:576-82.
17. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the a-Synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
18. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ. α-Synuclein in Lewy bodies. Nature 1997;388:839-40.
19. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 1998;152:367-72.
20. Trojanowski JQ, Lee VM-Y. Aggregation of neurofilaments and a-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson's disease and Lewy Body dementia. Arch Neurol 1998; 55:151-2.
21. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-70.
22. Ballard C, Patel A, Oyebode F, Wilcock G. Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Age Ageing 1996;25:209-13.
23. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-7.
24. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-22.
25. McKeith IG, Fairbairn AF, Bothwell RA, Moore PB, Ferrier IN, Thompson P, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of the Lewy body type. Neurology 1994;44:872-7.
26. Galasko D, Katzman R, Salmon DP. Clinical and neuropathological findings in Lewy body dementia. Brain Cogn 1996;31:176-85.
27. Weiner MF, Risser RC, Cullum CM, Honig L, White C III, Speciale S, et al. Alzheimer's disease and its Lewy body variant: A clinical analysis of postmortem verified cases. Am J Psychiatry 1996; 153:1269-73.
28. Mega MS, Masterman DL, Benson DF, Vinters HV, Tomiyasu U, Craig AH, et al. Dementia with Lewy bodies: Reliability and validity of clinical and pathological criteria. Neurology 1996;47:1403-9.
29. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer's disease and Parkinson's disease control groups. Neurology 1997;47: 1148-52.
30. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55: 1454-6.
31. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neural 1996;53:1265-8.
32. Goetz CH, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51:811-4.
33. Ala TA, Yang KH, Sung JH, Frey WH. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: A clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16-21.
34. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997;48:376-80.
35. Ganalingham KK, Byrne EJ, Thornton E, Sambrook MA, Bannister P. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997;62:243-52.
36. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-6.
37. Girling DM, Berrios GE. Extrapyramidal signs, primitive reflexes and frontal lobe function in senile dementia of the Alzheimer type. Br J Psychiatry 1990;157:888-93.
38. Galasko D, Kwo-on-Yuen PF, Klauber MR, Thai LJ. Neurological findings in Alzheimer's disease and normal aging. Arch Neurol 1990; 51:888-95.
39. Chen JY, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol 1991;48:1141-3.
40. Richards M, Stern Y, Marder K, Cote L, Mayeux R. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-9.
41. Mortimer JA, Ebbitt B, Jun SP, Rinch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-96.
42. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-81.
43. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997;54:969-75.
44. Drachman DA, O' Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease: "How far" rather than "how fast" best predicts the course. Arch Neurol 1990;47:851-6.
45. Stern Y, Liu X, Albert M, Brandt J, Jacobs DM, Del Castillo-Castaneda C, et al. Modeling the influence of extrapyramidal signs on the progression of Alzheimer's disease. Arch Neurol 1996;53:1121-6.
46. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of Parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch Neurol 1991;46:651-7.
47. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates of Extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-74.
48. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-8.
49. Schenk CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996;46:388-93.
50. Boeve BF, Silber MH, Ferman TK, Kokmen E, Smith GE, Ivnik RJ, et al. REM sleep disorder and degenerative dementia: An association likely reflecting Lewy body disease. Neurology 1998;52:363-70.
51. Salmon DP, Galasko D, Hansen LA, Masliah E, Butters N, Thai LJ, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996;31:148-65.
52. Shimomura T, Mori E, Yamashita H, Imamura T, Hirono N, Hashimoto M, et al. Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 1998;55:1547-52.
53. Sahgal A, Galloway PH, McKeith IG, Edwardson JA, Lloyd S. A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types. Dementia 1992;3:350-4.
54. Brown R, Marsden C. How common is dementia in Parkinson's disease? Lancet 1984;2:1262-5.
55. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992;49:492-7.
56. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Clinical features predicting dementia in idiopathic Parkinson's disease: A follow-up study. Neurology 1990;40:1222-4.
57. Marder K, Tang M-X, Cote LJ, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
58. Stern Y, Marder K, Tang M-X, Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993;46:1690-3.
59. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: A baseline study of the DATATOP cohort. Neurology 1990;40:1529-34.
60. Richards M, Stem Y, Marder K, Cote L, Mayeux R. Relationships between extrapyramidal signs and cognitive function in a community-dwelling cohort of patients with Parkinson's. Ann Neurol 1993; 33:267-74.
61. Boller F, Mizutani T, Roessman U. Parkinson's disease, dementia, and Alzheimer's disease: Clinicopathological correlations. Ann Neurol 1980;7:329-35.
62. Gaspar P, Grey F. Dementia in idiopathic Parkinson's disease. Acta Neuropathol 1984;64:43-52.
63. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50: 743-55.
64. Hakim A, Mathieson G. Dementia and Parkinson disease: A neuropathologic study. Neurology 1979;29:1209-14.
65. Bancher C, Braak H, Fischer P, Jellinger K. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease. Neurosci Lett 1993;162:179-82.
66. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52.
67. Heindel WC, Salmon DP, Shults CW, Walicke PA, Butters N. Neuropsychological evidence for multiple implicit memory systems: A comparison of Alzheimer's, Huntington's and Parkinson's disease patients. J Neurosci 1989;9:582-7.
68. Saint-Cyr JA, Taylor AE, Lang AE. Procedural learning and neostriatal damage in man. Brain 1988;111:941-59.
69. Pillon B, Dubois B, Bonnet AM, Esteguy M, Guimaraes J, Vigouret JM, et al. Cognitive slowing in Parkinson's disease fails to respond to L-dopa: The 15 objects test. Neurology 1989;36:1179-85.
70. Levin BE, Tomer R, Rey GJ. Cognitive impairments in Parkinson's disease. Neurol Clin 1992;10:471-85.
71. Maddox WT, Filoteo JV, Delis DC, Salmon DP. Visual selective attention deficits in patients with Parkinson's disease: A quantitative model-based approach. Neuropsychology 1996;10:197-218.
72. Cummings JL, Darkins A, Mendez M, Hill MA, Benson DF. Alzheimer's disease and Parkinson's disease: Comparison of speech and language alteration. Neurology 1988;38:680-4.
73. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-70.
74. Taylor AE, Saint-Cyr JA. The neuropsychology of Parkinson's disease. Brain Cogn 1995;28:281-96.
75. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995;346:699.
76. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991;14:283-95.
77. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-9.
78. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994;343:176.
79. Wilcock GK, Scott MI. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 1994;344:544.
80. Lebert F, Pasquier F, Souliez L. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998;13:516-9.
81. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients. Int Psychogeriatr 1998;10:229-38.
82. Kaufer DI, Catt KE, Lopez OL, DeKosky ST. Dementia with Lewy bodies: Response of delirium-like features to donepezil (letter). Neurology 1998;51:1512.